BriaCell Therapeutics Corp. Warrant
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $890.9K
- Price
- $0.1024
- % Change (Daily % change from the live per-ticker quote feed.)
- -10.29%
- Volume
- 117.7K
About
BriaCell Therapeutics Corp., a biotechnology company based in West Vancouver, Canada, is intensely focused on immuno-oncology, dedicated to engineering novel immunotherapies for cancer treatment. Its flagship compound, Bria-IMT, is a whole-cell cancer vaccine presently in Phase I/IIa clinical development, where it's being evaluated in conjunction with the investigational immunotherapy retifanlimab. The company's pipeline also includes Bria-OTS, a personalized, ready-to-use immunotherapy intended for advanced breast cancer, and BriaDx, a diagnostic tool for determining patient HLA types. BriaCell maintains a non-exclusive clinical trial collaboration with Incyte Corporation to explore the effects of combining various novel clinical candidates. Furthermore, a cooperative research and development agreement with the National Cancer Institute supports preclinical efforts to advance and test Bria-OTS cellular immunotherapy as a cancer therapy.
Quick stats
Shares outstanding8.7M
Computed float7.1M
Float / shares81.2%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001610820
Websitehttps://www.briacell.com
AI Summary
AI-generated1/20
majorpress release
BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer
FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a clinical study of Bria-PROS+ in prostate cancer Bria-PROS+ is BriaCell's next generation personalized immunotherapy for prostate cancer and incorporates additional immune activating components designed to enhance clinical efficacy Bria-PROS+ program previously awarded $2 million grant from the US National Cancer Institute PHILADELPHIA and VANCOUVER, British Columbia, Aug. 05, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Investigational New Drug (IND) application for Bria-PROS+ and issued a Study May Proceed letter, clearing the way for clinical evaluation of Bria-PROS+, its next generation, personalized, off-the-shelf, cell-based immunotherapy for prostate cancer. “We are pleased to announce FDA clearance of the IND for Bria-PROS+, our next-generation personalized immunotherapy for prostate cancer,” stated Dr. William V.